Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 11-13 April 2012

  • Email
  • Help

Press release

16/04/2012

Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 11-13 April 2012

CVMP opinions on veterinary medicinal products

The Committee adopted, by consensus, positive opinions for initial marketing authorisation applications for:

  • Poulvac E. coli, from Pfizer Limited, a vaccine for the active immunisation of chickens to reduce mortality and lesions associated with Escherichia coli serotype 078;
  • Porcilis ColiClos, from Intervet International B.V., a vaccine for the passive immunisation of piglets against E. coli and C. perfringens.

The Committee adopted, by consensus, positive opinions for type-II variation applications for:

  • Convenia to add a new smaller presentation;
  • Advocate regarding changes to the manufacturing process;
  • Equip WNV regarding changes to the manufacturing site.

Withdrawal of application

The applicant New A Innovation Limited B.V. withdrew its application for a new product at day 180 of the procedure before the CVMP could finalise its opinion.

In accordance with the Agency’s reflection paper on publication of withdrawals of marketing authorisation applications for veterinary medicinal products (EMEA/CVMP/42558/2006-Rev.1), the withdrawal letter and a withdrawal public assessment report (WEPAR) will be published on the Agency’s website shortly.

Community referrals and related procedures

The Committee started a procedure for all injectable and pour-on veterinary medicinal products containing doramectin that are intended for use in mammalian food producing species. The matter was notified to the Committee by the Netherlandsunder Article 35 of Directive 2001/82/EC, due to concerns relating to withdrawal periods and environmental risk mitigation measures.

The Committee concluded the referral procedure for Hipralona ENRO-S and its generics (enrofloxacin). The matter was referred to the Committee by Franceunder Article 35 of Directive 2001/82/EC in order to consider the benefit-risk balance of the products. The Committee adopted, by majority, an opinion concluding that the overall benefit-risk balance for the products concerned by this referral is positive and no changes in the product information were considered necessary.

The Committee noted a request for re-examination of the CVMP opinion adopted on 8 March 2012 in the context of a referral procedure under Article 35 of Directive 2001/82/EC for all veterinary medicinal products containingactive substances belonging to the class of flukicides for which no MRL has been established in milk and which are intended for use in ruminants producing milk for human consumption. The procedure will be initiated once the grounds for the re-examination have been submitted.

Maximum residue limits

The Committee adopted, by consensus, a positive opinion recommending the establishment of maximum residue limits (MRLs) for diclazuril in poultry. 

The Committee adopted, by consensus, a positive opinion for double-stranded RNA homologous to viral RNA coding for part of the coat protein and part of the intergenic region ofIsrael acute paralysis virus concluding that the establishment of maximum residue limits in bees is not necessary for the protection of public health and recommending its inclusion in table 1 of Commission Regulation No. 37/2010 of 22 December 2009.

The Committee adopted, by consensus, a positive opinion recommending the establishment of provisional maximum residue limits (MRLs) for eprinomectin in ovine and caprine species.

Scientific advice

The Committee agreed two scientific advice reports; on clinical development of an antimicrobial for cattle; and on quality, safety and clinical development of an immunological veterinary medicinal product for use in swine.

Minor use minor species / limited markets

Following the Committee’s review of one request for classification under the minor-use-minor-species (MUMS) / limited markets policy, which concerned a veterinary medicinal product for horses, the CVMP considered that the veterinary medicinal product for horses was indicated for MUMS / limited market and was eligible for financial incentives.

Pharmacovigilance

The Committee reviewed the periodic safety update reports (PSURs) for BTVPUR Alsap 2-4, Certifect, Equip WNV, Masivet, Netvax, Palladia, Prilactone and Rabigen SAG2 and concluded that no further action or changes to their product literature were required.

The Committee also reviewed the PSUR for Econor and recommended the following amendments to the product literature:

  • addition of new special warnings;
  • addition of a new special precaution for use in animals and humans (to wear gloves when handling the product);
  • inclusion of new information concerning pharmacodynamic properties.

Concept papers, guidelines and standard operating procedures

Immunologicals

The Committee adopted a guideline on requirements for the production and control of immunological veterinary medicinal products (EMA/CVMP/IWP/206555/2010) following the close of the public consultation. The guideline has been amended to take into account comments received during public consultation. The guideline provides guidance on important items related to the quality, safety and efficacy parts of the marketing authorisation dossier that are not sufficiently defined in the requirements of the existing texts.

Quality

The Committee adopted some questions and answers (Q&As) on the uniformity of dosage units following recent information that a harmonised approach (in the regions European Union (EU), United States and Japan) will not be possible from 1 January 2013 as had been envisaged. This document will replace several of the Q&As on this topic which were published on the Agency’s website in previous years and give guidance to both industry and assessors on how to now demonstrate compliance with the Ph. Eur. with regard to the uniformity of dosage units.

Regulatory issues

The Committee endorsed the standard operating procedure (SOP) in accordance with Article 78 of Directive 2001/82/EC, related to pharmacovigilance measures for veterinary medicinal products authorised in the EU (SOP/V/4025). The SOP was developed to ensure effective management of Article 78 procedures in a harmonised and transparent manner.

The Committee also noted the revised SOP on referrals in accordance with the provisions of Articles 34 and 35 of Directive 2001/82/EC, related to veterinary medicinal products authorised in the EU (SOP/V/4024). In the revised SOP, new templates have been applied and the procedure has been updated to reflect minor procedural changes and now includes the workflow of the re-examination process.

A question and answer document on issues which are usually addressed in discussions or correspondence with applicants/marketing authorisation holders during referrals regarding veterinary medicinal products to the CVMP has been published on the Agency’s website.

All the documents above will be available on the Agency’s website.

Other

Workshop on vaccine development against the Schmallenberg virus

The European Medicines Agency held a one-day workshop on 10 April 2012 to discuss issues related to the development of inactivated vaccines against the Schmallenberg virus.

Bringing together members of the Committee and its Immunologicals Working Party as well as European experts from academia and industry, the workshop included discussions of the latest epidemiological developments of the Schmallenberg virus as well as feedback from both regulators and industry on the experiences and challenges related to vaccines produced in response to avian influenza and bluetongue outbreaks. The workshop also discussed how the lessons learnt can be considered in the context of vaccine development for the Schmallenberg virus.

The outcomes from this workshop will be posted in a separate press release on the Agency’s website.

Procedural announcements by the Agency

The Agency will shortly be publishing a separate procedural announcement regarding electronic submissions for veterinary medicinal products and MRL applications. These should be fully compliant with the requirements of the guideline on the specifications for provision of an electronic submission (e-submission) for a veterinary medicinal product as of 1 June 2012.

The Agency will also shortly be publishing a separate procedural announcement regarding a revision of the application form for the establishment of MRLs to bring it in line with Regulation (EC) No. 470/2009 of the European Parliament and of the Council of 6 May 2009.

Name Language First published Last updated
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 11-13 April 2012 (English only) 2012-04-16  

How helpful is this page?

Average rating:

 Based on 1 ratings

Add your rating:

See all ratings
1 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more

Summaries of opinion

Maximum residue limits

There are currently no documents published in this section

Contact point:

Monika Benstetter or 
Sabine Haubenreisser
Tel. +44 (0)20 7418 8427
E-mail: press@ema.europa.eu